Adalgisa Condoluci
A5013201388- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- Genetic factors in colorectal cancer
- Acute Lymphoblastic Leukemia research
- Galectins and Cancer Biology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myeloid Leukemia Research
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
- Ultrasound in Clinical Applications
- Cancer-related gene regulation
- Sarcoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Molecular Biology Techniques and Applications
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- T-cell and B-cell Immunology
- Blood Coagulation and Thrombosis Mechanisms
- Pleural and Pulmonary Diseases
- Calcium signaling and nucleotide metabolism
- Pneumothorax, Barotrauma, Emphysema
Ente Ospedaliero Cantonale
2022-2025
Institute of Oncology Research
2017-2025
Università della Svizzera italiana
2019-2024
Institute of Experimental Endocrinology of the Slovak Academy of Sciences
2019
Ospedale San Giovanni Bellinzona
2016-2017
Università Campus Bio-Medico
2016
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways surrounding microenvironments diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups their underlying genomic abnormalities, pathway signatures, microenvironment compositions uncover biomarkers therapeutic vulnerabilities. studied 303 spleen samples...
The rationale for combining ibrutinib and venetoclax (IV) in chronic lymphocytic leukemia (CLL) treatment lies their complementary mechanisms of action. Studies investigating IV typically begin with a short initial course ibrutinib, followed by introduction limited duration, 12 months. SAKK34/17 (NCT03708003) is single-arm, open-label, multicenter, phase 2 trial evaluating the effectiveness modified schedule patients relapsed/refractory (R/R) CLL. No prior exposure to BTK- or BCL2-inhibitors...
Checkpoint blockade therapy (CBT) involving anti-PD1 antibodies represents the standard approach for cHL patients who do not respond to second-line therapy. Nonetheless, only 20% of relapsed/refractory (R/R) treated with CBT achieve complete remission. In this study, we extensively examined immune dynamics in eight R/R CBT, consisting four responders (CR) and experiencing disease progression (PD), by single cell analysis peripheral blood mononuclear cells (PBMCs). Our unique encompassed...
This study analyzed the genetics of classical Hodgkin lymphoma (cHL) by using circulating tumor DNA (ctDNA). Two genetic subtypes were identified, differing in instability mechanisms: one subtype (64% cases) showed a higher mutation load and fraction mutations associated with activation-induced cytidine deaminase microsatellite signatures, while other (36% exhibited chromosomal more somatic copy number alterations. Whole-genome duplication was common cHL compared to B-cell tumors emerged as...
Further line treatment of patients with advanced stage AL amyloidosis cardiac involvement is challenging. Venetoclax a promising option, especially in t(11;14) and BCL2 expression.In our multicentre observational study, we report the 3-year follow-up 9 advanced, relapsed or refractory BCL-2 expression > 50% plasma cells. At baseline, all had been previously treated daratumumab, revised Mayo III IV/ European modification 2004 IIIA IIIB (1/9 unclassified due to missing troponin T), 5/9 renal...
To advance the use of circulating tumor DNA (ctDNA) applications, their broad clinical validity must be tested in different treatment settings, including targeted therapies. Using prespecified longitudinal systematic collection plasma samples phase 1/2a LYM1002 trial (registered on www.clinicaltrials.gov as NCT02329847), we ctDNA for baseline mutation profiling, residual load quantification, and acquisition resistance mutations patients with lymphoma treated ibrutinib+nivolumab. Inclusion...
Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into insoluble beta-sheet rich structures that deposit extracellularly in different organs, eventually compromising their function. There are more than 30 proteins, known to be amyloidogenic “light chain” (AL)-amyloidosis being the most common type, followed by transthyretin (ATTR)-, and amyloid A (AA)-amyloidosis. rare disease an incidence around 10 patients 1 million inhabitants. Recently several...
Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity ATTR the variable presentation symptoms at early stages, historically meant treatment delays. Diagnostic tools therapy options have markedly improved recent years. first Swiss Amyloidosis Network (SAN) meeting (Zurich, Switzerland, January 2020) aimed to define consensus statement regarding diagnostic work-up...
Transthyretin (ATTR) amyloidosis is often diagnosed in an advanced stage, when irreversible cardiac damage has occurred. Lumbar spinal stenosis (LSS) may precede ATTR by many years, offering the opportunity to detect already at time of LSS surgery. We prospectively assessed prevalence ligamentum flavum tissue biopsy patients aged >50 years undergoing surgery for LSS.Ligamentum thickness was pre-operatively on axial T2 magnetic resonance imaging (MRI) slices. Tissue samples from were screened...